These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 729215)

  • 1. Comparative studies on the effect of hemoperfusion and hemodialysis on the elimination of some uremic toxins.
    Trznadel K; Walasek L; Kidawa Z; Lutz W
    Clin Nephrol; 1978 Dec; 10(6):229-31. PubMed ID: 729215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intradialytic changes of serum magnesium and their relation to hypotensive episodes in hemodialysis patients on different dialysates.
    Elsharkawy MM; Youssef AM; Zayoon MY
    Hemodial Int; 2006 Oct; 10 Suppl 2():S16-23. PubMed ID: 17022745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solute, amino acid, and hormone changes with coated charcoal hemoperfusion in uremia.
    Winchester JF; Ratcliffe JG; Carlyle E; Kennedy AC
    Kidney Int; 1978 Jul; 14(1):74-81. PubMed ID: 682427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The optimal timing of hemoperfusion component in combined hemodialysis-hemoperfusion treatment for uremic toxins removal.
    Li J; Li D; Xu Y; Wang A; Xu C; Yu C
    Ren Fail; 2015 Feb; 37(1):103-7. PubMed ID: 25421427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorbent recycling of ultrafiltrate in man--a 45-week crossover study.
    Shapiro WB; Schilb TP; Porush JG
    Clin Nephrol; 1986; 26 Suppl 1():S47-52. PubMed ID: 3829468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined hemodialysis-hemoperfusion treatment reduces the time of substitutive therapy in chronic uremia.
    Stefoni S; Feliciangeli G; Coli L; Scolari MP; Bonomini V
    Int J Artif Organs; 1981 Jul; 4(4):186-91. PubMed ID: 7327760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of blood purification on plasma levels of intact parathyroid hormone in patients with chronic renal failure.
    Liu J; Liu ZQ; Tao HQ
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Feb; 24(2):234-5. PubMed ID: 14965840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Correction of the composition of the dialyzing solution during its electrochemical regeneration].
    Maksimov EP; Leshchinskiĭ GM; Grinval'd VM; Fomicheva NN; Shadiev BSh
    Med Tekh; 2003; (2):8-10. PubMed ID: 12924213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dynamics of serum myoinositol concentration changes during haemodialysis and peritoneal dialysis.
    Trznadel K; Walasek L; Waldemar L
    Acta Med Pol; 1977; 18(1):55-61. PubMed ID: 855681
    [No Abstract]   [Full Text] [Related]  

  • 11. [The effect of hemodialysis and continuous ambulatory peritoneal dialysis on renal anemia].
    Stojimirović B; Grujić-Adanja G
    Srp Arh Celok Lek; 1997; 125(5-6):163-7. PubMed ID: 9265238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic renal disease patients with severe star fruit poisoning: hemoperfusion may be an effective alternative therapy.
    Chen LL; Fang JT; Lin JL
    Clin Toxicol (Phila); 2005; 43(3):197-9. PubMed ID: 15902795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Our experience with combined hemodialysis-hemoperfusion treatment in chronic uremia.
    Splendiani G; Albano V; Tancredi M; Daniele M; Pignatelli F
    Biomater Artif Cells Artif Organs; 1987; 15(1):175-81. PubMed ID: 3449135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A comparison of the efficiency of eliminating middle-weight molecules and myoinositol from plasma during hemoperfusion and hemodialysis in cases of chronic uremia].
    Trznadel K; Kidawa Z; Walasek L; Lutz W
    Pol Tyg Lek; 1978 Feb; 33(7):257-9. PubMed ID: 758030
    [No Abstract]   [Full Text] [Related]  

  • 15. [The effect of hemoperfusion through activated charcoal on middle molecular substances in the plasma during a long-term dialysis program].
    Mydlík M; Dzúrik R; Derzsiová K; Spustová V
    Cas Lek Cesk; 1983 Dec; 122(51):1573-6. PubMed ID: 6652672
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effect of hemodialysis and hemosorption on blood serum level of medium-molecular components in patients with chronic renal failure].
    Kozlov VV; Riabov SI; Dorofeeva TB; von Appen K; Spiridonov VN
    Ter Arkh; 1984; 56(7):77-81. PubMed ID: 6484840
    [No Abstract]   [Full Text] [Related]  

  • 17. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance.
    Gugliucci A; Mehlhaff K; Kinugasa E; Ogata H; Hermo R; Schulze J; Kimura S
    Clin Chim Acta; 2007 Feb; 377(1-2):213-20. PubMed ID: 17118352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in plasma concentrations of hypoxanthine and uric acid before and after hemodialysis.
    Shahbazian H; Zand Moghadam A; Ehsanpour A; Khazaali M
    Iran J Kidney Dis; 2009 Jul; 3(3):151-5. PubMed ID: 19617664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Initial results in the treatment with short-term dialysis].
    Dogliani M; Jeantet A; Coppo R; Canavese C; Camussi G; Giacchino F; Pacitti A
    Minerva Med; 1976 Jul; 67(35):2282-8. PubMed ID: 951050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Blood viscosity and the erythrocyte charge in patients with chronic kidney failure and suppurative intoxication and during the correction of these conditions by hemosorption and hemodialysis].
    Samoĭlov MV; Zakharchenko VN; Larionov SM; Naumov AG; Danilkov AP; Zakharova VD; Ivleva AI; Kudriavtsev IuV; Surikova TP
    Urol Nefrol (Mosk); 1993; (4):34-7. PubMed ID: 8310565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.